Protective effect of scFv-DAF fusion protein on the complement attack to acetylcholine receptor: A possible option for treatment of myasthenia gravis
- 22 November 2011
- journal article
- research article
- Published by Wiley in Muscle & Nerve
- Vol. 45 (5) , 668-675
Abstract
Introduction: Autoantibody‐induced complement activation, which causes disruption of the postsynaptic membrane, is recognized as a key pathogenic factor in myasthenia gravis (MG). Therefore, specific targeting of complement inhibitors to the site of complement activation is a potential therapeutic strategy for treatment of MG. Methods: We assessed expression of single‐chain antibody fragment–decay accelerating factor (scFv‐DAF), comprising a single‐chain fragment scFv1956 based on the rat complement inhibitor DAF in prokaryotic systems, and studied its inhibitory effect on complement deposition in vitro. Results: The recombinant conjugate scFv‐DAF completely retained the wild‐type binding activity of scFv1956 to AChR and inhibited complement activation of DAF in vitro. Conclusions: We found that scFv‐DAF could bind specifically to TE671 cells, and it is significantly more potent at inhibiting complement deposition than the untargeted parent molecule DAF. scFv‐DAF may be a candidate for in vivo protection of the AChR in MG. Muscle Nerve, 2012Keywords
This publication has 44 references indexed in Scilit:
- Deficiency of decay accelerating factor and CD59 leads to crisis in experimental myastheniaExperimental Neurology, 2006
- The membrane attack pathway of complement drives pathology in passively induced experimental autoimmune myasthenia gravis in miceClinical and Experimental Immunology, 2006
- Complement membrane attack is required for endplate damage and clinical disease in passive experimental myasthenia gravis in Lewis ratsClinical and Experimental Immunology, 2006
- Coupling complement regulators to immunoglobulin domains generates effective anti-complement reagents with extended half-lifein vivoClinical and Experimental Immunology, 2002
- Human and rodent decay‐accelerating factors (CD55) are not species restricted in their complement‐inhibiting activitiesImmunology, 2000
- Mutational Analysis of the Active Site and Antibody Epitopes of the Complement-inhibitory Glycoprotein, CD59Journal of Experimental Medicine, 1997
- Myasthenia GravisNew England Journal of Medicine, 1994
- Flexibility of the myosin heavy chain: direct evidence that the region containing SH1 and SH2 can move 10 .ANG. under the influence of nucleotide bindingBiochemistry, 1988
- A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye BindingAnalytical Biochemistry, 1976
- A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnalytical Biochemistry, 1976